Elveția - franceză - Swissmedic (Swiss Agency for Therapeutic Products)

alexion pharma gmbh - sebelipasum alfa - solution à diluer pour perfusion - sebelipasum alfa 2 mg, trinatrii citras dihydricus corresp. natrium 3.2 mg, acidum citricum monohydricum, albuminum seri humani, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - à long terme enzymothérapie substitutive chez les patients de tous Âges souffrant de lal-absence - biotechnologika

Canada - franceză - Health Canada

pfizer canada ulc - taliglucérase alfa - poudre pour solution - 200unité - taliglucérase alfa 200unité - enzymes

Canada - franceză - Health Canada

biomarin international limited - Élosulfase alfa - solution - 1mg - Élosulfase alfa 1mg - enzymes

Uniunea Europeană - franceză - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - velmanase alfa - alpha-mannosidose - d'autres tractus digestif et le métabolisme des produits, - le traitement des manifestations non neurologiques chez les patients avec léger pour modérer l'alpha-mannosidose.

Canada - franceză - Health Canada

takeda canada inc - vélaglucérase alfa - poudre pour solution - 400unité - vélaglucérase alfa 400unité - enzymes

Canada - franceză - Health Canada

alexion pharma gmbh - sébélipase alfa - solution - 2mg - sébélipase alfa 2mg - enzymes

Uniunea Europeană - franceză - EMA (European Medicines Agency)

ultragenyx germany gmbh - vestronidase alfa - la mucopolysaccharidose de type vii - les enzymes - mepsevii est indiqué pour le traitement de la non-manifestations neurologiques de la mucopolysaccharidose de type vii (mps vii; sly syndrome).

Canada - franceză - Health Canada

biomarin international limited - cerliponase alfa - solution - 150mg - cerliponase alfa 150mg - enzymes

Uniunea Europeană - franceză - EMA (European Medicines Agency)

ptc therapeutics international limited - eladocagene exuparvovec - métabolisme des acides aminés, erreurs innées - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.

Uniunea Europeană - franceză - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a - pegunigalsidase alfa - maladie de fabry - d'autres tractus digestif et le métabolisme des produits, - elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of fabry disease (deficiency of alpha-galactosidase).